Primary Central Nervous System Lymphoma

Iyavut Thaipisuttikul and Craig Nolan
Memorial Sloan-Kettering Cancer Center
United States

1. Introduction

Primary central nervous system lymphoma (PCNSL) is characterized by extranodal malignant lymphomas arising in the brain, spinal cord, CSF, and eyes in the absence of lymphoma outside the nervous system at the time of diagnosis (Deckert & Paulus, 2007). By definition, this excludes CNS involvement of systemic lymphomas and angiotropic lymphomas (Schlegel et al., 2000). The incidence of PCNSL in the United States was noted to be increasing in immunocompetent, immunosuppressed, and immunodeficient individuals over the past several decades (Schabet, 1999) with more than six-fold increase from 1973 to 1997, while the incidence of non-Hodgkin lymphoma (NHL) increased 81% during the same period (Olson et al., 2002). However, this increase in incidence seems to be leveling off in the past decade. According to the most recent Central Brain Tumor Registry Statistical Report (February 2011), PCNSL occurs at an annual incidence of 0.46 cases per 100,000 person-years in the United States during 2004-2007. PCNSL accounted for 2.4% of all primary brain tumors in the United States. There is a slight male predominance with a male-to-female ratio of 1.38. The peak incidence is between age 75 and 84. The median age in most studies is 55-65. The age at diagnosis in AIDS patients is much younger with mean age reported in the fourth decade (Deckert & Paulus, 2007; Fine et al., 1993).

2. Pathology

2.1 Histological classification

There is no generally accepted histologic classification system for PCNSL. Although the CNS in humans is devoid of B-cell and germinal center structure, more than 90% of PCNSLs are diffuse large B-cell non-Hodgkin lymphomas, while T-cell antigens are usually restricted to small reactive lymphocytes (Paulus, 1999). Primary T-cell lymphomas of the CNS, Burkitt lymphomas and other lymphoma types are rare. Although PCNSL is not specifically included in the current Revised European-American Lymphoma (REAL) classification (Harris et al., 1994), the most recent WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (2008) classified PCNSL as a separate entity under “Aggressive lymphoma/leukemia” (Jaffe, 2009).

2.2 Basic pathology features

Supratentorial locations are more common (87%) and lesions usually are located in periventricular areas involving the thalamus, basal ganglia, and corpus callosum (Bataille et
al., 2000). The demarcation of the lesions from the surrounding brain is variable and this can make it resemble glioma due to diffuse borders. Necrotic areas are seen in AIDS patients (Bhagavathi & Wilson, 2008). The cells of primary diffuse large B-cell lymphoma (DLBCL) arising in the brain are morphologically similar to systemic forms. Perivascular cuffs of malignant and reactive lymphocytes are commonly seen around the larger blood vessels. They are seldom found around vessels less than 8 µm in diameter and are not present around small capillaries with a diameter less than 4 µm. This feature, however, is not specific for PCNSL but can also be seen in metastatic lymphoma to CNS (Aho et al., 1993).

2.3 Immunohistochemical profile and gene expression

Recently, three molecularly distinct forms of systemic DLBCL in immunocompetent patients were identified as germinal center B-cell–like (GCB), the activated B-cell–like (ABC) and the so-called type III (Rosenwald et al., 2002). This classification is based on immunohistochemical markers: CD10 for early germinal center, BCL-6 (which is a zinc-finger transcriptional repressor required for the formation of the GC) for early and late germinal center, MUM1 for germinal center/early post-germinal center and CD138 for post-germinal center. Initial studies found PCNSL to be of GCB origin based on BCL-6 expression (Larocca et al., 1998) and ongoing mutational activity (Thompsett et al., 1999). BCL-6 gene mutations and BCL-6 protein expression have been reported in 50% and 100% of PCNSL, respectively. More recent studies found that most PNCL cases expressed both BCL-6 and MUM1 but lacked CD10 and CD138 which suggested late germinal center/early post-germinal center stage of differentiation (Braaten et al., 2003; Camilleri-Broet et al., 2006). Although BCL-6 expression is associated with a favorable prognosis in systemic DLBCL, its prognostic significance is less clear in PCNSL with studies showing favorable prognosis (Braaten et al., 2003; Song et al., 2011), poor prognosis (Chang et al., 2003) and no impact on outcome (Camilleri-Broet et al., 2006). The fact that PCNSL has poorer prognosis compared with systemic DLBCL and its high-grade nature may contribute to this finding. Recent studies aiming to find a “CNS signature” by comparing molecular features of PNCSL with nodal large B-cell NHL found different expression in several genes (Rubenstein et al., 2006; Tun et al., 2008). Interleukin-4 (IL-4) was found to be highly expressed by tumor vasculature as well as by tumor cells in CNS lymphomas. Moreover, expression of activated form of STAT6, a mediator of IL-4 signaling, was also found in PCNSL and was associated with short survival in patients treated with a high-dose intravenous methotrexate-containing regimen (Rubenstein et al., 2006).

3. Pathogenesis

The most important risk factor for PCNSL is immunodeficiency, whether inherited or acquired, which includes Wiskott-Aldrich syndrome, AIDS, immunosuppressive therapy following organ transplantation and other immunosuppression for cancer and autoimmune treatments. Evidence of EBV genome is present in more than 95% of AIDS-related PCNSL which suggests its major role in lymphoma pathogenesis in this group. It was hypothesized that EBV infection leads to polyclonal B-cell activation in the context of aberrant B-cell regulation and that the inherent genetic instability of the EBV-infected and immortalized B-cells eventually leads to MYC gene rearrangement and the development of malignant lymphoma (Knowles, 2003). However, the etiology of PCNSL in immunocompetent patients is still unclear. Three hypotheses have been proposed to explain how lymphomas arise and grow primarily in the CNS:
1. B-cells may be transformed outside the CNS and then develop adhesion molecules specific for CNS tropism (Deckert & Paulus, 2007). The expression of BCL-6 found in most patients suggests that PCNSL has been exposed to a germinal center microenvironment outside the CNS. Recently, some specific genes are thought to be involved in CNS tropism of PCNSL. SPP1, a member of the extracellular matrix (ECM)-related genes associated with various aspects of cancer biology, and DDR1, a member of a family of receptor tyrosine kinases involved in cell adhesion in several brain tumors, were found to be upregulated in PCNSL (Tun et al., 2008). In one study, lymphoma cells from a PCNSL patient were implanted subcutaneously in an athymic mouse. At 16 weeks, the lymphoma cells were shown to home to CNS blood vessels through autopsy while there was no evidence of lymphoma cells at any sites including the subcutaneous implantation site (Jiang et al., 2010). This study supports the theory of highly selective tropism of PCNSL.

2. Systemic lymphoma cells may be eradicated by an intact immune system. The B-cell–activating factor of the TNF family (BAFF), produced locally by astrocytes, together with the shielding of the brain from the immune system, might provide a safe environment for PCNSL while systemic lymphoma cells outside CNS are not protected (Krumholz et al., 2005).

3. Polyclonal inflammatory cells in the brain may transform to monoclonal PCNSL. This theory is supported by occasional reports of “sentinel lesions” which are biopsy-proven demyelinating or non-neoplastic lesions but ultimately lead to PCNSL months to years later (Alderson et al., 1996; Ng et al., 2007; Yang & Wu., 2007; Habek et al., 2008). However, infectious or inflammatory CNS diseases are rarely reported preceding PCNSL (Deckert & Paulus, 2007).

4. Clinical features
Most patients present with neurological symptoms and signs rather than systemic “B” symptoms (Batchelor et al., 2006). Neurological symptoms depend primarily on the location of the tumor and the rapidity of tumor progression with cerebral symptoms being most common followed by ocular, leptomeningeal and spinal cord. In the largest retrospective analysis of 248 immunocompetent patients with PCNSL, the most common type of clinical signs on admission was focal neurological deficit (70%). Neuropsychiatric symptoms (43%), increased intracranial pressure (33%), seizures (14%) and vitreous involvement (4%) were noted. In 7% of patients, neurological signs were preceded by systemic manifestations such as gastrointestinal symptoms or febrile respiratory illnesses (Bataille et al., 2000).

5. Neuroimaging
Recognizing the radiographic features of PCNSL is crucial as corticosteroids should not be used before biopsy and unnecessary surgical resection can be avoided. PCNSL lesions are typically isodense to hyperdense on CT scan and isointense to hypointense on T2-weighted MRI. Highly packed abnormal cells are thought to be responsible for the increased attenuation. Internal calcification is unusual in CNS lymphomas unless the patient has undergone prior chemotherapy or radiation treatment (Erdag et al., 2001). The enhancement pattern is usually homogeneous. Ring-like enhancement is rare in immunocompetent patients but commonly seen in immunodeficient patients. In the largest MRI series of 100 immunocompetent patients with PCNSL, a single lesion was seen in 65% and multiple lesions were seen in 35%. Lesions...
are located in a cerebral hemisphere (38%), deep gray matter (16%), corpus callosum (14%), ventricle wall and choroid plexus (12%), and cerebellum (9%). The contrast enhancement of the cerebral or spinal lesions was rated as strong in 85% and moderate in 10%. Absence of enhancement was seen in 1% (Kuker et al., 2005). Restricted diffusion of protons, although rare, has been reported and might be useful in non-enhancing PCNSL patients (Barajas et al., 2010; Fischer et al., 2010; Zacharia et al., 2008). A more recent study of MRI findings in 26 patients with PCNSL reported findings of open-ring enhancement in 2 patients. The open-ring enhancement is considered highly specific for brain demyelination, but it was noted that the ring is thick and not uniform in PCNSL compared with a thin and uniform open-ring pattern in brain demyelination. A newly described “notch sign”, which is an abnormally deep depression at the tumor margin, was found in 3 patients (Zhang et al., 2010). The sensitivity and specificity of these findings need further validation.

a. Typical MRI appearance of PCNSL shows homogeneous enhancement. Stereotactic biopsy confirmed PCNSL

b. Patient with suspected PCNSL. Pathology showed glioblastoma.

Fig. 1. MRI of patients with suspected PCNSL

6. Diagnostic evaluation

In 2005, the International PCNSL Collaborative Group (IPCG) published a guideline to standardize baseline evaluation, response criteria and outcome measures for patients enrolled onto clinical trials for PCNSL (Abrey et al., 2005). The recommendation has increasingly become accepted as a standard baseline evaluation for all immunocompetent patients with suspected PCNSL.

6.1 Pathologic evaluation

Histopathology is mandatory because other intracranial processes may also have similar appearance on imaging and transient response to corticosteroids (Zaki et al., 2004). A
stereotactic needle biopsy is the procedure of choice due its low risk and no survival benefit of surgical resection. However, the diagnosis can also be established by positive CSF cytology or a vitrectomy specimen. Establishing immunophenotype characteristics of the tumors is recommended as the information may be useful for future development and application of targeted therapies. Corticosteroids significantly increase false negative biopsy results and should not be given to any patients suspected of having PCNSL before biopsy. Osmotic agents should be the first choice if patients need urgent treatment for increased intracranial pressure (Weller, 1999). Recently, CSF biomarkers of PCNSL such as MicroRNAs (Baraniskin et al., 2011) and antithrombin III (Roy et al., 2008), were discovered in order to facilitate early and noninvasive diagnosis. Further investigations are needed to validate the use of these biomarkers in clinical practice.

6.2 Clinical evaluation
A complete physical and neurologic examination should be recorded. Special attention should be given to peripheral lymph nodes, the liver and spleen. Testicular examination should be performed in older men as testicular lymphoma is the most common lymphoma in men over age sixty and has a higher risk of CNS metastasis (Hill & Owen, 2006). Age and performance status are widely used in prognostic models for PCNSL and should be recorded in every patient. Baseline cognitive function should be evaluated by using the Mini-Mental Status Examination (MMSE) as treatment-related neurocognitive complications are common.

6.3 Laboratory evaluation
In addition to routine hematologic function, hepatic and renal functions are important to ensure the safety of using high-dose methotrexate. The level of creatinine clearance above 50 to 60 mL/min is adequate. Serum LDH was found to be one of the prognostic variables. HIV infection should be tested in every patient with PCNSL.

6.4 Extent-of-disease evaluation
Choice of therapy depends on the extent of lesions. This should include evaluation of CNS, body and bone marrow. Gadolinium-enhanced MRI of the brain is recommended unless there is a contraindication; contrast-enhanced CT scan can be used. CSF examination with documented opening pressure should be performed in every patient unless contraindicated. CSF should be collected before surgical biopsy or 1 week after to avoid a false positive result. A minimum of 3 mL and ideally 10 mL should be sent for cytology. CSF total protein is mandatory as an important prognostic factor. CSF obtained from ventricles via Ommaya reservoir usually shows a much lower total protein level than CSF from lumbar puncture and the result should be interpreted with caution. The following studies are optional: cell count, beta2-microglobulin, immunoglobulin H gene rearrangement, and flow cytometry. Although cytopathology is a gold standard, flow cytometry was recently found to have better sensitivity and specificity in detection of leptomeningeal involvement in PCNSL and systemic lymphoma (Hegde et al., 2005; Schroers et al., 2010). Gadolinium-enhanced MRI of the spinal cord is required for those who have symptoms or signs of spinal cord involvement. A detailed ophthalmologic work up with slit-lamp examination should be performed to exclude vitreous, retinal, or optic nerve involvement. CT scan of the chest, abdomen, and pelvis and bone marrow biopsy with aspirate are minimum staging
procedures. Body positron emission tomography (PET) imaging is commonly used as an additional tool for staging of PCNSL and a recent study showed that 18F-Fluorodeoxyglucose (FDG) PET may be more sensitive than conventional body staging (Mohile et al., 2008). Some patients in this study were found to have FDG-avid foci outside the thoracic, abdominal, and pelvic cavities, underscoring a major limitation of the conventional scan. Testicular ultrasound should be performed to rule out testicular lymphoma in older men.

7. Prognosis and prognostic factors

Overall, PCNSL carries a worse prognosis compared with non-CNS extranodal DLBCL. With supportive care alone, the averaged survival is 3.3 months from diagnosis (Henry et al., 1974). With active chemotherapy/radiotherapy treatment, median survival up to 51 months has been reported (Gavrilovic et al., 2006). Prognosis of AIDS-related PCNSL is particularly poor with the median survival of untreated patients measured in weeks (Kasamon et al., 2005). Attempts to prognosticate individual patients have been focused on a clinical scoring system and phenotypic/genetic features. As mentioned above, BCL-6 expression is associated with a favorable prognosis in systemic DLBCL but its role as a prognostic marker in PCNSL will need further validation. In addition, STAT6 and co-expression of p53 and c-Myc may correlate with poor survival outcome (Camilleri-Broet et al., 2006; Chang et al., 2003). Three clinical prognostic scoring systems have been proposed.

The Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic score, published in 2006, uses age and Karnofsky performance score (KPS) to identify patients into 3 classes; Class 1: age ≤ 50, Class 2: age >50 and KPS ≥ 70, and Class 3: age >50 and KPS <70. Based on MSKCC and RTOG data set, a median overall survival (OS) was 5-8 years, 2-3 years and 1 year or less for class 1, 2, and 3, respectively. This system was developed from retrospective analysis of data from 282 patients and was validated using an external data set of 152 patients treated on RTOG PCNSL trials. This system has the advantage of simplicity and widespread applicability. Its limitation is the possible selection bias from using data from a single institution (Abrey et al., 2006).

The International Extranodal Lymphoma Study Group (IELSG), published in 2003, uses a 5-point scoring system which consists of age > 60, Eastern Cooperative Oncology Group (ECOG) performance status ≥1, elevated serum lactate dehydrogenase (LDH) level, elevated CSF total protein (>45 mg/dL if <60 years old, >60 mg/dL if >60 years old), and involvement of deep brain structures. This score was developed from a retrospective analysis of data from 48 treating centers which identified 105 patients who had complete data from a total cohort of 378 patients. This system identifies patients into three risk groups based on a number of unfavorable features; 0-1, 2-3 and 4-5. A 2-year OS was 80%, 48%, and 15% for patients with scores of 0-1, 2-3 and 4-5, respectively. Its limitation is that less than one-third of the total cohort had complete data. This emphasizes the complexity of the system; the median follow-up was relatively short, only 24 months (Ferreri et al., 2003).

The four point Nottingham/Barcelona score, published in 2004, uses a prediction score giving 1 point for each adverse prognostic factor; age ≥ 60, performance status ≥ 2, and multifocal and/or meningeal disease (advanced stage). This scoring system was derived from 77 consecutive patients treated on one of two clinical trials. A median survival of 55 months, 41 months, 32 months and 1 month was associated with a score of 0, 1, 2 and 3, respectively. Its limitation is a small number of patients included in this score. It also failed to discriminate
prognosis for those patients who fell into the two middle categories and was only significant for differentiating the patients with the best and worst prognostic factors (Bessell et al., 2004).

8. Follow-up assessment and response criteria

In addition to clinical evaluation, a follow-up gadolinium-enhanced MRI scan every two months or at the time of treatment change is recommended. A detailed ophthalmologic examination and CSF cytology are required only if the initial studies are positive or clinically indicated.

The IPCG response criteria (Abrey et al., 2005), proposed in 2005, identifies patients based on their response to therapy as follow:

- **Complete response (CR):** This requires complete disappearance of all enhancing abnormalities on gadolinium-enhanced MRI while the patients have not been on corticosteroid treatment for at least 2 weeks. Negative CSF cytology and/or negative ophthalmologic examination are required if these studies were initially positive.
- **Unconfirmed complete response (CRu):** This includes patients who meet the CR criteria but are currently on corticosteroids which may decrease the enhancement seen on MRI as well as patients who continue to have persistent minor abnormalities on MRI or ophthalmologic examination which are not consistent with tumor infiltration.
- **Partial response (PR):** This includes patients who have >50% decrease in the contrast-enhancing lesion seen on MRI as compared with baseline imaging while corticosteroid treatment does not affect the determination of response. Ophthalmologic examination should show a decrease in the vitreous cell count or retinal/optic nerve cellular infiltrate but may continue to show persistent malignant or suspicious cells. CSF examination may be negative or continue to show persistent malignant or suspicious cells.
- **Stable disease:** This is defined as less than a PR but is not progressive disease.
- **Progressive disease:** This includes patients who have >25% increase in the contrast-enhancing lesion seen on MRI as compared with baseline, or develop any new site of disease, or have an increase in the vitreous cell count or retinal/optic nerve cellular infiltrate.
- **Relapse disease:** Patients with prior CR or CRu who develop any new site of disease will qualify for relapsed disease.

9. Therapy of newly diagnosed PCNSL

In contrast to other CNS metastases, PCNSL cells spread diffusely into the CNS parenchyma (Aho et al., 1993). Thus, therapies targeted to the tumor site alone are never curative. For this reason, surgical resection has no survival benefit. Corticosteroids, systemic chemotherapy and whole-brain radiation therapy (WBRT) are the mainstay of PCNSL therapy. Involvement of organs outside of the CNS is very rare, making systemic prophylaxis a less important consideration. The eye, however, is an important site for tumor spread at presentation and relapse. Dedicated therapy to the orbits is required since most chemotherapeutic agents do not achieve cytotoxic concentrations within the eye and standard whole-brain radiation fields do not involve the orbits.

9.1 Corticosteroids

The effects of corticosteroids in PCNSL are not solely mediated by a reduction of cerebral edema but also involve cytotoxic activity. Corticosteroids trigger the apoptosis cascade and
an oncolytic response in malignant lymphocytes via the endogenous steroid receptor. The initial response rate up to 40% has been reported with 15% complete remission and 25% partial remissions (DeAngelis et al., 1990). Relapse after the initial corticosteroid-responsive period is common. The mechanism which underlies corticosteroid resistance during chronic treatment and the withdrawal period is still poorly understood. Long-term use of corticosteroids should be avoided to minimize their secondary complications.

9.2 Radiation therapy

Historically, conventional treatment of PCNSL had been WBRT and corticosteroids up until the use of effective chemotherapy over the past 20 years. The concerning issues of radiation therapy are its short-lived benefit and delayed neurotoxicity. The role of WBRT as the only mainstay of treatment was established in the prospective trial of cranial irradiation alone, Radiation Therapy Oncology Group (RTOG) 83-15, which was published in 1992. This trial demonstrated a dramatic CT scan response to WBRT with CR in 62% and partial CR in 19% of patients. However, this finding did not translate into improved long-term control or survival with a median survival of only 12 to 18 months and a 5-year survival rate of less than 5% in the trial (Nelson et al., 1992). A secondary analysis of this trial along with another RTOG trial showed that RT dose escalation by incorporating a boost to areas of bulky disease did not improve disease control or survival (Corn et al., 2000). Since then, WBRT has been incorporated into various chemotherapy regimens during consolidation after induction with methotrexate (MTX) alone or with other chemotherapeutic drugs. The optimal dose of WBRT in the setting of combined-modality treatment of PCNSL is not established. The usual dose used in combined-modality therapy trials is 4000-4500 cGy. The combined-modality approaches followed by WBRT is associated with a 2-year OS of 43% to 73% (Ferreri et al., 2003). However, treatment-related toxicity was reported in 25%-49% of patients (Gavrilovic et al., 2006; Omuro et al., 2005; Thiel et al., 2010). Neurotoxicity is especially common in patients older than 60. For this reason, two strategies have been proposed to decrease the risk of neurotoxicity.

One strategy is to defer WBRT in patients who achieve a complete response with initial chemotherapy and are older than 50-60 years old. The major concern with this approach is that eliminating the use of whole-brain radiotherapy could compromise disease control. This strategy is supported by the findings from 2 large retrospective analyses which showed that the addition of WBRT to combination chemotherapy did not improve survival in patients treated with high-dose methotrexate (MTX), but was associated with improvements in long-term disease control (Ekenel et al., 2008; Ferreri et al., 2002). Recently, a large prospective randomized phase 3 trial, aiming to address this issue, was published in 2010 (Thiel et al., 2010). This trial randomized 551 patients to receive six cycles of MTX–based chemotherapy alone versus MTX-based chemotherapy with consolidation WBRT (4500 cGy), but only 318 patients treated per protocol were included in the primary analysis of noninferiority. The primary end point was noninferiority comparison of OS and the planned secondary end point was progression-free survival (PFS). There was no significant difference in OS between the two groups, but analysis of PFS suggested a trend for improved disease control in patients assigned to WBRT. There are many issues which interfere with the interpretation of this trial such as high number of protocol violations and the fact that this study failed to meet the predetermined criteria for noninferiority; thus, drawing any conclusions should not be appropriate for a noninferiority trial. Despite
absence of flawless evidence, many experts agree that patients who have a CR and are older than 50-60 years, should not receive WBRT because data suggest that any improvement in outcome is outweighed by the consequences of neurotoxicity (Abrey, 2011; Deangelis, 2011). Whether WBRT in the setting of combined-modality therapy is safe in younger patients, and the risk-benefit balance between chances of cure versus long-term toxicity, have to be further studied.

The other strategy is to use reduced-dose WBRT. This strategy was first explored in a subset of patients in the RTOG 93-10 trial which studied combined-modality therapy with full dose WBRT (4500 cGy). In this subset, patients who achieved a CR after induction chemotherapy were treated with a hyperfractionated regimen of 3600 cGy delivered at 1200 cGy twice a day. There was no statistical difference in PFS and OS for this group despite the dose reduction. However, this regimen also did not eliminate the development of severe neurotoxicity (Fisher et al., 2005). The Nottingham and Barcelona group reported that young patients who received a low total dose (3060 cGy) of WBRT after achieving a CR had a significantly higher risk of relapse and shorter OS than patients who received standard (4500 cGy) radiotherapy (Bessell et al., 2002). In contrast to previous findings, a trial using a reduced-dose WBRT of 2340 cGy in 17 patients who achieved a CR following combined immunochemotherapy showed that reduced-dose WBRT did not compromise disease control and was not associated with neurocognitive decline (Shah et al., 2007). The strategy of using reduced-dose WBRT will need to be further studied in a large prospective multicenter trial.

9.3 Chemotherapy

Due to the poor outcome from WBRT alone, the use of chemotherapy for newly diagnosed PCNSL, either alone or as induction before WBRT, is widely accepted. The commonly used regimen for treatment of systemic NHL is the four-drug combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Although CHOP can induce an initial response in PCNSL, the responses were not durable and relapses occurred rapidly. Inability to cross the blood–brain barrier (BBB) is the main limitation of most chemotherapy drugs. There is no doubt that MTX at a higher dose than that used for NHL is the most active single agent against PCNSL. Its efficacy has been confirmed in several phase 2 trials. However, controversies have involved the dosing strategy of MTX, the choice between MTX monotherapy and MTX-based multi-drug regimens, what multi-drug chemotherapy regimens should be used and the use of intrathecal/intraventricular chemotherapy. An alternative method of MTX delivery is BBB disruption (BBBD) in conjunction with intra-arterial (IA) MTX. This approach, in combination with intravenous etoposide and cyclophosphamide, was evaluated in the pooled analysis of 149 newly diagnosed PCNSL patients. The overall response rate (ORR) was 81.9% and median OS was 3.1 years. Although this approach gives a comparable result to conventional intravenous high-dose MTX, it requires an experienced team and invasive procedures (Angelov et al., 2009).

9.3.1 MTX dosing strategy

Three different doses have been studied in the clinical trials assessing activity of single-agent high-dose MTX: MTX 8 g/m² every 2 weeks deferring WBRT until failure (Batchelor et al., 2003; Herrlinger et al., 2005); MTX 3.5 g/m² every 3 weeks followed by WBRT(Glass et al., 1994; Ferreri et al., 2009); and MTX 1 g/m² immediately before WBRT(Abrey et al., 1998;
management of CNS Tumors

O’Brien et al., 2006). The dose of 8 g/m² yielded an apparently different ORR in Europe compared to the United States (51% for the German trial and 68% for the American trial). It should be noted that dose reduction due to impaired creatinine clearance was indicated in 45% of patients in the trials using the dose of 8 g/m², whereas in the 3.5 g/m² trials only a few patients needed a reduction in MTX dose. Both 8 g/m² trials and 3.5 g/m² trials resulted in a comparable 3-year OS rate of 30%-45%. The response rate has not been assessed in trials using MTX 1 g/m² but a reported 3-year OS rate was 45%-50%.

It was suggested in one study that a dose of MTX of 3 g/m² is considered the lowest dose to obtain the minimum CSF-steady-state concentration of MTX required to treat acute lymphocytic leukemia (>5 X 10⁻⁷ mol/L) (Lippens & Winograd, 1988). This study also showed that the MTX concentration in the CSF cannot be predicted by determining the plasma concentration. The rate of infusion also plays a major role in delivering MTX through the BBB. Rapid infusion of 3 g/m² of MTX over 3 h will consistently achieve therapeutic concentrations in the CSF, whereas this concentration is not reliably obtained with a 24-h continuous infusion of 8 g/m² (Vassal et al., 1990; Tetef et al., 2000). Currently, there is no clear evidence of difference in outcome of various doses of MTX above 3 g/m². In the absence of intrathecal treatment, the available data lend support to a recommendation for a MTX dose of at least 3 g/m² given over 3 h in all patients (Morris & Abrey, 2009).

9.3.2 MTX monotherapy versus MTX-based multi-drug regimens

The efficacy of single agent MTX and multi-drug MTX-based regimens (with or without WBRT) has been proven in several phase 2 trials. Recently, a prospective randomized multi-center phase 2 trial with a primary end point of CR, studied the use of four cycles of MTX (3.5 g/m²) alone or in combination with cytarabine (2 g/m² every 12 h on days 2 and 3 of each cycle) followed by WBRT. Despite the expected increase in the toxicity, the combination arm was associated with an increased complete remission rate from 18% to 46%. The estimated 3-year failure-free survival was 21% following MTX alone and 38% following combined treatment. The estimated 3-year OS was 32% following MTX alone and 46% following combined treatment. This trial clearly showed the advantage to multi-drug MTX-based regimens over single agent MTX (Ferreri et al., 2009).

9.3.3 What multi-drug chemotherapy regimens should be used?

A combination of MTX, procarbazine and vincristine (MPV), given in 5 cycles followed by consolidation cytarabine (with or without WBRT), has been proposed based on their different mechanisms of action and different toxicity profiles. Although vincristine usually does not cross the BBB it may be able to reach the tumor where the BBB is disrupted. Procarbazine is an oral lipophilic alkylating drug that can cross the normal BBB. This regimen was studied in the RTOG 93-10 trial along with intraventricular MTX, WBRT and two cycles of cytarabine with a median OS of 37 months. The 2-year OS was 64% and 5-year OS was 32% (DeAngelis et al., 2002). Another study used this regimen along with Rituximab, a monoclonal antibody that targets the CD20 antigen, and WBRT, showed a 2-year OS of 67%. The ORR was 93% (Shah et al., 2007).

A combination of MTX and cytarabine was proposed and its efficacy established in a recent trial (Ferreri et al., 2009). The rationale of using cytarabine after MTX is the continuance of the exposure of proliferating cells to S-phase cytostatics and the increase of cytarabine cytidine triphosphate formation and DNA incorporation, with a consequent increased cytotoxicity (Carrabba et al., 2010).
A regimen consisting of MTX, teniposide, carmustine and methylprednisolone plus intrathecal chemotherapy and subsequent WBRT was used in the European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group phase II trial 20962. A 2-year OS was 69% and 3-year OS was 58%. It should be noted that 10% of patients died, probably because of infectious complications (Poortmans et al., 2003).

The MATILDE regimen consists of MTX, cytarabine, idarubicin and thiotepa. This regimen followed by WBRT resulted in an ORR of 83% and a 5-year OS of 41% (Ferreri et al., 2006).

A combination of MTX and temozolomide without radiotherapy or intrathecal chemotherapy was evaluated in one study of 23 elderly (age >60) patients. This regimen resulted in a favorable toxicity profile and comparable results to other regimens with a CR in 55% and a median OS of 35 months (Omuro et al., 2007).

### 9.3.4 Intrathecal / Intraventricular chemotherapy

The benefit of routine use of intrathecal MTX (12 mg x 5 doses, alternating with high-dose MTX) in newly diagnosed PCNSL patients was evaluated in a case-controlled retrospective study. Patients who already received high-dose MTX (≥ 3.5 g/m²) did not benefit from additional intrathecal/intraventricular MTX treatment (Khan et al., 2002). Another large multicenter retrospective study of 370 patients also failed to demonstrate any survival benefit of adjunct intrathecal MTX to a conventional high-dose MTX-based regimen (Ferreri et al., 2002). Currently, there is no evidence to support the routine use if intrathecal MTX in patients who receive high-dose MTX and have negative CSF cytology. Despite lack of information supporting this approach, intrathecal chemotherapy is being used in clinical practice as a supplement to systemic chemotherapy but restricted to patients who have positive CSF or receive MTX less than 3 g/m² (Morris & Abrey, 2009).

### 9.4 Immunotherapy

The survival benefit of adding rituximab to the standard treatment of systemic NHL has been established (Coiffier et al., 2010). Although rituximab has been incorporated into some treatment regimens for PCNSL (Shah et al., 2007), the benefit of using this approach is unclear. Recently, the largest series of patients with PCNSL treated with IV rituximab monotherapy has been published. Twelve patients were enrolled in the series. Confirmed radiographic responses were seen in 36% of patients (3 CR, 1 PR) (Batchelor et al., 2011). The benefit of rituximab in PCNSL, optimal dose, and treatment schedule will need to be further studied in larger multi-center trials.

### 9.5 High-dose chemotherapy with stem-cell transplant

High-dose chemotherapy supported by autologous stem cells transplant (HDC/ASCT) has been used as salvage therapy in patients who fail conventional chemo-radiotherapy or as upfront during consolidation phase. The strategy is to increase drug delivery through the BBB with high-dose chemotherapy which may eliminate the need for WBRT. The combinations used in the treatment of PCNSL can be carmustine, etoposide, cytarabine, and melphalan (BEAM) or thiotepa-based conditioning regimens. Two recent Phase II multi-institutional trials have established its feasibility. The OSHO-53 phase II study trial studied 16 patients (out of 23) who achieved CR/PR after induction chemotherapy and were treated with high-dose busulfan and thiotepa with ASCT followed by response-adapted WBRT. In the transplanted group, estimated 2-year EFS and OS were 56% and 61%, respectively
Management of CNS Tumors

Montemurro et al., 2007). The multicenter phase II study of the GOELAMS group studied 17 patients (out of 25) who responded to initial chemotherapy and were treated with a BEAM regimen with ASCT followed by WBRT. One patient died. With a median follow-up of 34 months, 16 patients were in CR at the time of the analysis (Colombat et al., 2006). Direct comparison between trials is difficult, but thiopeta-based regimens seem to be associated with better results than BEAM-based regimens. It should be noted that 3 patients in the OSHO trial and all patients in the GOELAMS trial still required WBRT after HDC/ASCT. These results, although encouraging, should be interpreted with caution because of the possibility of selection biases in which patients in these trials tended to be younger than patients in other studies and all chemotherapy resistant patients were excluded.

10. Salvage therapy for relapse and refractory PCNSL

Relapse after initial therapy has been reported in 30%-60% of patients (Gavrilovic et al., 2006; Glass et al., 1994). Approximately 10%-15% of immunocompetent patients have primary refractory PCNSL (Reni et al., 2001). Prognosis for patients with relapsed PCNSL is poor, with a median survival of approximately 4.5 months. Choices of therapy including WBRT (Hottinger et al., 2007), repeated high-dose MTX (Plotkin et al., 2004), temozolomide (Reni et al., 2004), rituximab (Batchelor et al., 2011), intraventricular rituximab (Rubenstein et al., 2007), topotecan (Fischer et al., 2006; Voloschin et al., 2008), other combinations such as the PCV regimen (procarbazine, lomustine, and vincristine) (Herrlinger et al., 2000), temozolomide plus rituximab (Enting et al., 2004), ifosfamide plus etoposide and cytarabine (Arellano-Rodrigo et al., 2003), and HDC/ASCT (Soussain et al., 2008) have been studied with median OS ranging from 3.5-62 months. Currently, there is no consensus regarding which salvage regimen to use in this setting. Therapeutic decisions should be based on individual patient characteristics.

11. Primary intraocular lymphoma

Primary intraocular lymphoma (PIOL) is a subset of PCNSL, which initially presents in the eye with or without simultaneous CNS involvement (Chan et al., 2002). It is distinct from secondary intraocular lymphoma which arises outside the CNS and later involves the eye. Metastatic lymphoma commonly involves the uveal tract, whereas PIOL typically involves the vitreous, subretinal pigment epithelial space and optic nerve head. The disease is bilateral in 80% of patients. Approximately 20% of PCNSL patients have ocular involvement at diagnosis (Davis, 2004). The diagnosis is based on positive CSF cytology, diagnostic vitrectomy, vitreous aspiration, or brain biopsy. When PIOL is suspected, CSF cytology should be performed before diagnostic vitrectomy as it is less invasive. The processing and examination of CSF and vitreous are the same and include cytology, immunocytochemistry, flow cytometry, cytokine, and molecular analyses (Sen et al., 2009). Optimal management of PIOL is not clearly defined. The goal of treatment is to eradicate tumor cells in the eyes and prevent subsequent CNS relapse. Historically, the primary focus has been on local therapy with ocular radiation and intraocular MTX. Ocular radiation has long been used with doses of 3500 to 4000 cGy and was found to have a 58% disease-free survival at 2 years in one small series (Margolis et al., 1980). Because bilateral disease is very common (>80%), radiation has to be given to both eyes. However, ocular radiotherapy can cause radiation
keratopathy, dry eyes, cataracts, radiation retinopathy, and papillopathy (Gunduz et al., 2006). Intravitreal MTX was also reported to have excellent local disease control (Frenkel et al., 2008). However, in a large retrospective series of an international PCNSL collaborative group, 102 patients who had additional local ocular therapy (ocular radiotherapy, intravitreal MTX, or both) in addition to their therapy for PCNSL did not have a statistically significant decreased risk of failing in the eyes, and OS was not impacted (Grimm et al., 2008). Recently, there have been efforts to use HD-MTX for the treatment of POL. Systemic high-dose MTX of 8 g/m² was found to achieve a therapeutic concentration in the aqueous humor and vitreous (Batchelor et al., 2003). There has been concern regarding the efficacy of systemic chemotherapy as the sole therapy in patients with PIOL. Although CR may be achieved, relapse is common. In one report of 14 patients with ocular lymphoma and concurrent PCNSL treated with high-dose MTX, thiotepa, vincristine and intrathecal cytarabine/MTX, CR was achieved in 79% but relapse occurred a median of 16.5 months following diagnosis (Sandor et al., 1998). In another retrospective study, all patients who were treated with chemotherapy alone had CNS or ocular relapse. Despite unclear information, directed ocular treatment is still being used commonly with or without systemic chemotherapy (Frenkel et al., 2008). Recently, intraocular rituximab has been studied as CD20 is found in over 90% of tumors and is absent in normal intraocular tissues. Initial case series of intravitreal rituximab showed that it is tolerated in human eyes without reduction in visual acuity (Kitzmann et al., 2007). Futures studies are needed to confirm these findings.

12. References


Primary Central Nervous System Lymphoma


Management of CNS Tumors is a selected review of Central Nervous System (CNS) tumors with particular emphasis on pathological classification and complex treatment algorithms for each common tumor type. Additional detailed information is provided on selected CNS tumor associated disorders.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
